CN113348182A - Lag-3抗体及其医药用途 - Google Patents

Lag-3抗体及其医药用途 Download PDF

Info

Publication number
CN113348182A
CN113348182A CN202080006879.4A CN202080006879A CN113348182A CN 113348182 A CN113348182 A CN 113348182A CN 202080006879 A CN202080006879 A CN 202080006879A CN 113348182 A CN113348182 A CN 113348182A
Authority
CN
China
Prior art keywords
antibody
framework region
seq
chain framework
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080006879.4A
Other languages
English (en)
Other versions
CN113348182B (zh
Inventor
崔东冰
徐英倩
李冠英
王利利
李海荣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Hailu Biotechnology Co ltd
Original Assignee
Shanghai Hailu Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hailu Biotechnology Co ltd filed Critical Shanghai Hailu Biotechnology Co ltd
Publication of CN113348182A publication Critical patent/CN113348182A/zh
Application granted granted Critical
Publication of CN113348182B publication Critical patent/CN113348182B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LAG‑3抗体及其医药用途。该抗体能够特异性地与LAG‑3的胞外域，并具有优秀的亲和力与特异性；且该抗体为功能性抗体，其具有阻断LAG‑3与其配体MHC II结合的活性。此外，进一步对该抗体进行了人源化改造，并验证了该抗体功能的方法。该抗体可通过调节人免疫功能治疗多种癌症或免疫性疾病。

Description

PCT国内申请，说明书已公开。

Claims (22)

  1. PCT国内申请，权利要求书已公开。
CN202080006879.4A 2019-12-30 2020-12-30 Lag-3抗体及其医药用途 Active CN113348182B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019114002147 2019-12-30
CN201911400214 2019-12-30
PCT/CN2020/141475 WO2021136392A1 (zh) 2019-12-30 2020-12-30 Lag-3抗体及其医药用途

Publications (2)

Publication Number Publication Date
CN113348182A true CN113348182A (zh) 2021-09-03
CN113348182B CN113348182B (zh) 2022-07-12

Family

ID=76685943

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080006879.4A Active CN113348182B (zh) 2019-12-30 2020-12-30 Lag-3抗体及其医药用途

Country Status (2)

Country Link
CN (1) CN113348182B (zh)
WO (1) WO2021136392A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115873116A (zh) * 2021-09-29 2023-03-31 中山康方生物医药有限公司 抗lag3抗体、药物组合物及用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104804094A (zh) * 2005-08-22 2015-07-29 伊缪诺金公司 Ca6抗原特异性细胞毒性偶联物及其应用方法
WO2017219995A1 (zh) * 2016-06-23 2017-12-28 江苏恒瑞医药股份有限公司 Lag-3抗体、其抗原结合片段及其医药用途
US20190225687A1 (en) * 2017-02-22 2019-07-25 I-Mab Anti-lag-3 antibodies and uses thereof
WO2020257789A2 (en) * 2019-06-21 2020-12-24 Single Cell Technology, Inc. Anti-tim-3 antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11339218B2 (en) * 2017-05-10 2022-05-24 Zhejiang Shimai Pharmaceutical Co., Ltd. Human monoclonal antibodies against LAG3 and uses thereof
CN109748963A (zh) * 2017-11-01 2019-05-14 三生国健药业（上海）股份有限公司 一种抗lag-3的单克隆抗体及其制备方法和用途
CN110204614B (zh) * 2018-02-28 2022-07-12 广州誉衡生物科技有限公司 抗人lag-3单克隆抗体及其制备方法和用途
CN110305215B (zh) * 2018-03-20 2023-11-03 基石药业 新型抗lag-3抗体多肽
CN110343179B (zh) * 2018-04-02 2024-03-08 上海博威生物医药有限公司 结合淋巴细胞活化基因-3(lag-3)的抗体及其用途
CN110343178B (zh) * 2018-04-03 2022-07-22 上海开拓者生物医药有限公司 抗人lag-3单克隆抗体及其应用
CN110606892B (zh) * 2018-06-14 2023-09-26 华博生物医药技术（上海）有限公司 一种高亲和力高生物活性的lag-3抗体及其应用
CN110615840A (zh) * 2018-06-19 2019-12-27 信达生物制药(苏州)有限公司 全人源的抗lag-3抗体及其应用
CN110172099B (zh) * 2018-08-16 2020-03-03 上海健信生物医药科技有限公司 抗lag-3人源化单克隆抗体分子，抗原结合片段及其医药用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104804094A (zh) * 2005-08-22 2015-07-29 伊缪诺金公司 Ca6抗原特异性细胞毒性偶联物及其应用方法
WO2017219995A1 (zh) * 2016-06-23 2017-12-28 江苏恒瑞医药股份有限公司 Lag-3抗体、其抗原结合片段及其医药用途
CN108472349A (zh) * 2016-06-23 2018-08-31 江苏恒瑞医药股份有限公司 Lag-3抗体、其抗原结合片段及其医药用途
US20190225687A1 (en) * 2017-02-22 2019-07-25 I-Mab Anti-lag-3 antibodies and uses thereof
WO2020257789A2 (en) * 2019-06-21 2020-12-24 Single Cell Technology, Inc. Anti-tim-3 antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
XIAOJIE YU: "Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy", 《MABS》 *
邓伟伟: "LAG-3 在头颈鳞癌预示不良预后且阻断LAG-3 可以加强抗肿瘤免疫效果", 《 第十一次全国口腔颌面——头颈肿瘤学术会议暨2017山东省口腔医学会口腔颌面外科分会学术年会暨山东省口腔颌面外科高层论坛暨山东省口腔医学会口腔颌面一头颈肿瘤分会成立大会》 *

Also Published As

Publication number Publication date
CN113348182B (zh) 2022-07-12
WO2021136392A1 (zh) 2021-07-08

Similar Documents

Publication Publication Date Title
US11912763B2 (en) Antibody targeting CLDN18.2, bispecific antibody, ADC, and CAR, and applications thereof
CN109715667B (zh) 抗-gprc5d抗体、结合gprc5d和cd3的双特异性抗原结合分子及其用途
CN108350076B (zh) 抗-bcma抗体，结合bcma和cd3的双特异性抗原结合分子及其用途
CN102574921B (zh) 双特异性死亡受体激动型抗体
ES2625798T3 (es) Anticuerpos humanos que se unen a CXCR4 y usos de los mismos
KR101348472B1 (ko) Ｃｄ20에 대한 인간 모노클로날 항체
US11639388B2 (en) CD3 antigen binding fragment and application thereof
BR112020016944A2 (pt) Domínios variáveis de anticorpo que alvejam cd33 e uso dos mesmos
KR102608028B1 (ko) 인간 원형질막 소포 관련 단백질 pv-1에 특이적으로 결합하는 단일클론항체 및 이의 제조방법과 용도
JP7384835B2 (ja) Ｃｄ３に特異的な抗体及びその使用
AU2021311701A1 (en) Anti-CTLA-4 antibody and use thereof
US20220064314A1 (en) Cd137 agonist antibodies and uses thereof
JP2024506626A (ja) 抗ｃｄ１１２ｒ抗体及びその用途
CN113348182B (zh) Lag-3抗体及其医药用途
JP2023533793A (ja) 治療用抗体およびそれらの使用
CN111670197A (zh) 治疗癌症的抗前胃泌激素抗体与免疫疗法的组合疗法
CN113811329A (zh) 抗pd-1抗体和其用途
US11807683B2 (en) Antibody binding TIM-3 and use thereof
CN116113433A (zh) 结合人cd38的抗体、其制备方法和用途
WO2023134657A1 (zh) 抗cldn18.2和4-1bb的双特异性抗原结合蛋白及其用途
US20230382995A1 (en) Molecules binding pd-l1 and uses thereof
WO2023143478A1 (en) Novel anti-cd4 and anti-pd-l1 bispecific antibodies
WO2023098785A1 (zh) 抗4-1bb抗体及其用途
RU2696202C1 (ru) Гуманизация антител кролика с использованием универсального каркаса антитела
TW202330604A (zh) 靶向ｂａｆｆ—ｒ的抗體及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant